Analyst interview in Swedish with Ziccum’s CEO following the release of Q3, 2024 report

  • by

    • Watch Ziccum’s CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid in Swedish on the highlights of Ziccum’s Q3 2024 report and the company’s current status.

    Ziccum’s CEO, Ann Gidner, shares a number of exciting developments, including an invitation to participate in a large international consortium with key industrial and academic partners, the on-going inhaled mRNA/LNP animal studies, and the current status of the collaboration with ReCode Therapeutics.

    Please watch the entire interview here: https://youtu.be/5fUJ-wSJGX8

    For more information about Ziccum, please contact:

    Ann Gidner
    CEO, Ziccum AB
    Mail: gidner@ziccum.com
    Mobile: +46 722140141

    Jonas Ekblom
    Chairman of the Board, Ziccum AB
    Mail: ekblom@ziccum.com
    Mobile: +46 736777540

    Ziccum’s Certified Adviser is
    Vator Securities AB

    About Ziccum

    Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

    Attachments

    Analyst interview in Swedish with Ziccum's CEO following the release of Q3, 2024 report

    Analyst interview in Swedish with Ziccum's CEO following the release of Q3, 2024 report